Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
peptides
Biotech
GemVax's peptide drug fails phase 2a neurodegenerative trial
Korea's GemVax revealed that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy.
Fraiser Kansteiner
Oct 29, 2024 11:28am
MBX aims for $136M IPO to take rival to Ascendis into phase 3
Sep 9, 2024 11:59am
MBX files for IPO to take challenger to Ascendis into phase 3
Aug 26, 2024 9:40am
Baker Lab AI makes strides in drug-like peptides
Apr 25, 2024 2:00pm
Genentech signs off on $1B biobucks to expand PeptiDream collab
Sep 20, 2023 7:14am
Theratechnologies halts lead cancer trial over efficacy concerns
Dec 2, 2022 5:35am